## Ionis to present at upcoming investor conferences

## May 26, 2021

CARLSBAD, Calif., May 26, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conferences:

-

- William Blair 41<sup>st</sup> Annual Growth Stock Conference on Tuesday, June 1, 2021
- Goldman Sachs 42<sup>nd</sup> Annual Global Healthcare Conference on Wednesday, June 9, 2021
- Nasdaq 44<sup>th</sup> Investor Conference on Tuesday, June 15, 2021
- BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology on Tuesday, June 22, 2021

The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check <u>www.ionispharma.com</u> for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

## **About Ionis Pharmaceuticals**

For more than 30 years, lonis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.

To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.

C View original content to download multimedia: <u>http://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-</u> 301299234.html

## SOURCE Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D., Vice President, Investor Relations, 760-603-2741; Ionis Pharmaceuticals Media Contact: Roslyn Patterson, Vice President, Corporate Communications, 760-603-4679